A protective role for programmed death 1 in progression of murine adriamycin nephropathy

Kidney International

Volumn 70, Issue 7, 2006, Pages 1244-1250

  Qin, X H ^a   Lee, V W S ^a   Wang, Y P ^a   Zheng, G P ^a   Wang, Y ^a   Alexander, S I ^b   Harris, D C H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Chronic kidney failure; Doxorubicin; Focal glomerulosclerosis; Macrophages; Peripheral tolerance; Programmed cell death 1 protein

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD28 ANTIGEN; CREATININE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE TIME EFFECT RELATION; FOCAL GLOMERULOSCLEROSIS; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TUBULE CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEINURIA; T LYMPHOCYTE ACTIVATION;

ACTINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; CREATININE; CRICETINAE; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; KIDNEY TUBULES; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PEPTIDES; PROTEINURIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAINING AND LABELING; TIME FACTORS;

EID: 33748923964     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000345     Document Type: Article

References (31)

1. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000; 58: 1797-1804.
2. Taal MW, Omer SA, Nadim MK, Mackenzie HS. Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression. Curr Opin Nephrol Hypertens 2000; 9: 323-331.
3. van Kooten C. Blockade of costimulatory pathways of T-cell activation: the solution to acute and chronic rejection? Curr Opin Nephrol Hypertens 1999; 8: 675-680.
4. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
5. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545.
6. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5336-5341.
7. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
8. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
9. Okazaki T, Tanaka Y, Nishio R et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9: 1477-1483.
10. Prokunina L, Gunnarsson I, Sturfelt G et al. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 2004; 50: 327-328.
11. Probst HC, McCoy K, Okazaki T et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005; 6: 280-286.
12. Rangan GK, Pippin JW, Couser WG. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 2004; 66: 1838-1848.
13. Schoop R, Wahl P, Le Hir M et al. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant 2004; 19: 2713-2720.
14. Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol 2005; 115: 184-191.
15. Okazaki T, Maeda A, Nishimura H et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 13866-13871.
16. Ozkaynak E, Wang L, Goodearl A et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002; 169: 6546-6553.
17. Carter L, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643.
18. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002; 169: 3581-3588.
19. Kishimoto K, Sandner S, Imitola J et al. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest 2002; 109: 1471-1479.
20. Cai G, Karni A, Oliveira EM et al. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol 2004; 230: 89-98.
21. Bennett F, Luxenberg D, Ling V et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003; 170: 711-718.
22. Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
23. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp 2003; 252: 67-88 (discussion 88-91, 106-114).
24. Sandner SE, Clarkson MR, Salama AD et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005; 174: 3408-3415.
25. Aramaki O, Shirasugi N, Takayama T et al. Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation 2004; 77: 6-12.
26. Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-69.
27. Blazar BR, Carreno BM, Panoskaltsis-Mortari A et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003; 171: 1272-1277.
28. Tsushima F, Iwai H, Otsuki N et al. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol 2003; 33: 2773-2782.
29. Salama AD, Chitnis T, Imitola J et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003; 198: 71-78.
30. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987; 32: 691-699.
31. Wu H, Wang Y, Tay YC et al. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 2005; 67: 2178-2186.